Which closed-end funds own Abbott Laboratories?
18 active closed-end funds report this security in their latest N-PORT filing, with a combined reported value of $216M. Security type: common equity. Country: United States. CUSIP 002824100 · ISIN US0028241000 · ticker ABT.
Holdings are historical filings (report dates May 29, 2026 – Jul 31, 2026; N-PORT becomes public ~60 days after quarter end), not live positions. Weights are percent of each fund’s net assets. Different instruments of one issuer (shares, bonds, preferreds) are separate securities — see related securities below.
Funds holding this security
| Fund | Category | Weight | Value (USD) | Balance | Fund net assets | Prem/disc | Report date |
|---|---|---|---|---|---|---|---|
| THQ abrdn Healthcare Opportunities Fund | Healthcare | 3.74% | $39.4M | 433,683 sh | $1.1B | 7.8% discount | Jun 30, 2026 |
| THW abrdn World Healthcare Fund | Healthcare | 2.40% | $16.5M | 182,305 sh | $689M | 3.7% discount | Jun 30, 2026 |
| BME BlackRock Health Sciences Trust | Healthcare | 1.89% | $10.8M | 119,561 sh | $573M | 2.8% discount | Jun 30, 2026 |
| HQH abrdn Healthcare Investors | Healthcare | 1.82% | $24.9M | 273,941 sh | $1.4B | 7.1% discount | Jun 30, 2026 |
| EXG Eaton Vance Tax-Managed Global Diversified Equity Income Fund | Global Equity | 1.01% | $32.8M | 309,946 sh | $3.3B | 10.6% discount | Jul 31, 2026 |
| EVT Eaton Vance Tax-Advantaged Dividend Income Fund | U.S. Equity | 0.98% | $30.4M | 287,313 sh | $3.1B | 8.9% discount | Jul 31, 2026 |
| ETG Eaton Vance Tax-Advantaged Global Dividend Income Fund | Global Equity | 0.80% | $21.6M | 204,620 sh | $2.7B | 11.1% discount | Jul 31, 2026 |
| ETO Eaton Vance Tax-Advantaged Global Dividend Opportunities Fund | Global Equity | 0.73% | $5.5M | 52,151 sh | $756M | 11.8% discount | Jul 31, 2026 |
| GRX Gabelli Healthcare & WellnessRx Trust | Healthcare | 0.68% | $1.6M | 17,200 sh | $228M | NAV unavailable | Jun 30, 2026 |
| NIE Virtus Equity & Convertible Income Fund | Convertible Securities | 0.66% | $5.2M | 49,025 sh | $786M | 10.3% discount | Jul 31, 2026 |
| ETB Eaton Vance Tax-Managed Buy-Write Income Fund | Covered Call / Option Income | 0.60% | $3M | 32,539 sh | $495M | 10.4% discount | Jun 30, 2026 |
| BMEZ BlackRock Health Sciences Term Trust | Healthcare | 0.58% | $6.3M | 68,889 sh | $1.1B | NAV unavailable | Jun 30, 2026 |
| ETW Eaton Vance Tax-Managed Global Buy-Write Opportunities Fund | Covered Call / Option Income | 0.34% | $3.9M | 43,123 sh | $1.2B | 11.2% discount | Jun 30, 2026 |
| SPXX Nuveen S&P 500 Dynamic Overwrite Fund | Covered Call / Option Income | 0.31% | $9.1M | 99,958 sh | $2.9B | NAV unavailable | Jun 30, 2026 |
| ACV Virtus Diversified Income & Convertible Fund | Convertible Securities | 0.26% | $983K | 9,300 sh | $380M | 4.9% discount | Jul 31, 2026 |
| QQQX Nuveen NASDAQ 100 Dynamic Overwrite Fund | Covered Call / Option Income | 0.15% | $2.4M | 26,882 sh | $1.6B | 3.3% discount | Jun 30, 2026 |
| GDV Gabelli Dividend & Income Trust | U.S. Equity | 0.06% | $2M | 21,750 sh | $3.4B | 13.0% discount | Jun 30, 2026 |
| GOF Guggenheim Strategic Opportunities Fund | Multi-Asset | 0.00% | $14.1K | 165 sh | $2.8B | 11.2% discount | May 29, 2026 |
18 positions. Source: SEC Form N-PORT via market-data vendor re-serve. Funds without an N-PORT on file cannot appear here.
Also listed in filings as: ABBOTT LABORATORIES.
Related securities from the same issuer
| Security | Type | Funds holding |
|---|---|---|
| Abbott Laboratories | debt security | 2 |
| Abbott Laboratories | debt security | 1 |
| Abbott Laboratories | debt security | 1 |
| Abbott Laboratories | debt security | 1 |
| Abbott Laboratories | debt security | 1 |
| Abbott Laboratories | debt security | 1 |
| Abbott Laboratories | debt security | 1 |
Issuer-level search for “ABT” → · Compare two funds’ portfolios →